tetano
Editor, Senior Moderator
J Infect Chemother
. 2023 May 11;S1341-321X(23)00114-9.
doi: 10.1016/j.jiac.2023.05.004. Online ahead of print. Effectiveness of intravenous peramivir for the treatment of influenza A/H3N2 and influenza B/Victoria in hospitalized children
Jinna Wang[SUP] 1 [/SUP], Hongdou Chen[SUP] 2 [/SUP], Lie Zhuo[SUP] 2 [/SUP], Ying Guo[SUP] 3 [/SUP], Xu Wang[SUP] 2 [/SUP], Lina Chen[SUP] 2 [/SUP], Fangfang Zheng[SUP] 2 [/SUP]
Affiliations
Objective: To optimize the medication administered to children with influenza, we evaluated the effectiveness of peramivir in hospitalized children with influenza A/H3N2 and influenza B/Victoria.
Methods: A retrospective study was conducted from October 2019 to March 2020 in children aged 29 days to 18 years with influenza A/H3N2 or B/Victoria. A total of 97 patients were enrolled and treated with intravenous infusion of peramivir.
Results: The duration of influenza virus nucleic acid positivity in the influenza A/H3N2 group (3 days) was shorter than that in the influenza B/Victoria group (4 days) (P = 0.008). The remission time of fever symptoms in the influenza A/H3N2 group was 14 h, which was significantly shorter than that in the influenza B/Victoria group (26 h) (P = 0.042). In the 6-18 years age group, the median duration of virus nucleic acid positivity for children with influenza B/Victoria (4 days) was longer than that for children with influenza A/H3N2 (2 days) (P = 0.005). The incidence of adverse drug reactions (ADRs) with peramivir in the influenza A/H3N2 group and the influenza B/Victoria group was 2.04% (n = 1/49) and 4.17% (n = 2/48), respectively (P = 0.617).
Conclusions: A difference in the effectiveness of peramivir against different subtypes of influenza was observed. Compared to those infected with influenza B/Victoria, the children infected with influenza A/H3N2 experienced a significantly shorter duration of influenza virus nucleic acid positivity and remission time of fever symptoms.
. 2023 May 11;S1341-321X(23)00114-9.
doi: 10.1016/j.jiac.2023.05.004. Online ahead of print. Effectiveness of intravenous peramivir for the treatment of influenza A/H3N2 and influenza B/Victoria in hospitalized children
Jinna Wang[SUP] 1 [/SUP], Hongdou Chen[SUP] 2 [/SUP], Lie Zhuo[SUP] 2 [/SUP], Ying Guo[SUP] 3 [/SUP], Xu Wang[SUP] 2 [/SUP], Lina Chen[SUP] 2 [/SUP], Fangfang Zheng[SUP] 2 [/SUP]
Affiliations
- PMID: 37178975
- DOI: 10.1016/j.jiac.2023.05.004
Objective: To optimize the medication administered to children with influenza, we evaluated the effectiveness of peramivir in hospitalized children with influenza A/H3N2 and influenza B/Victoria.
Methods: A retrospective study was conducted from October 2019 to March 2020 in children aged 29 days to 18 years with influenza A/H3N2 or B/Victoria. A total of 97 patients were enrolled and treated with intravenous infusion of peramivir.
Results: The duration of influenza virus nucleic acid positivity in the influenza A/H3N2 group (3 days) was shorter than that in the influenza B/Victoria group (4 days) (P = 0.008). The remission time of fever symptoms in the influenza A/H3N2 group was 14 h, which was significantly shorter than that in the influenza B/Victoria group (26 h) (P = 0.042). In the 6-18 years age group, the median duration of virus nucleic acid positivity for children with influenza B/Victoria (4 days) was longer than that for children with influenza A/H3N2 (2 days) (P = 0.005). The incidence of adverse drug reactions (ADRs) with peramivir in the influenza A/H3N2 group and the influenza B/Victoria group was 2.04% (n = 1/49) and 4.17% (n = 2/48), respectively (P = 0.617).
Conclusions: A difference in the effectiveness of peramivir against different subtypes of influenza was observed. Compared to those infected with influenza B/Victoria, the children infected with influenza A/H3N2 experienced a significantly shorter duration of influenza virus nucleic acid positivity and remission time of fever symptoms.